Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study
Articolo
Data di Pubblicazione:
2020
Citazione:
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study / Reinisch, Walter; Panaccione, Remo; Bossuyt, Peter; Baert, Filip; Armuzzi, Alessandro; Hébuterne, Xavier; Travis, Simon; Danese, Silvio; Sandborn, William J; Schreiber, Stefan; Berg, Sofie; Zhou, Qian; Kligys, Kristina; Neimark, Ezequiel; Suleiman, Ahmed A; D'Haens, Geert; Colombel, Jean-Frederic. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 26:10(2020), pp. 1562-1571-1571. [10.1093/ibd/izaa025]
Abstract:
CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Crohn’s disease; biologics; clinical pharmacology; inflammatory bowel disease
Elenco autori:
Reinisch, Walter; Panaccione, Remo; Bossuyt, Peter; Baert, Filip; Armuzzi, Alessandro; Hébuterne, Xavier; Travis, Simon; Danese, Silvio; Sandborn, William J; Schreiber, Stefan; Berg, Sofie; Zhou, Qian; Kligys, Kristina; Neimark, Ezequiel; Suleiman, Ahmed A; D'Haens, Geert; Colombel, Jean-Frederic
Link alla scheda completa:
Pubblicato in: